Navigation Links
New Hope for Relief of Chronic Sciatica
Date:4/30/2009

New hope for hundreds of thousands of people suffering from chronic sciatica was revealed this week in a Phase II randomized, double-blind, placebo-controlled trial. Researchers from the Walter Reed Army Medical Center reported that localized (epidural) administration of etanercept, a unique therapeutic that neutralizes TNF (tumor necrosis factor), holds promise as a treatment for sciatica. Epidural etanercept for sciatica was invented by a California physician, Edward Tobinick MD, Director of the Institute for Neurological Research in Los Angeles.

Los Angeles, CA (PRWEB) April 30, 2009 -- New hope for hundreds of thousands of people suffering from chronic sciatica was revealed this week in a Phase II randomized, double-blind, placebo-controlled trial. Researchers from the Walter Reed Army Medical Center reported(1) that localized (epidural) administration of etanercept, a unique therapeutic that neutralizes TNF (tumor necrosis factor), holds promise as a treatment for sciatica. Epidural etanercept for sciatica was invented by a California physician, Edward Tobinick MD[2. Sciatica, nerve root pain radiating down the leg, is most often associated with a herniated disc in the lower back. Basic science research has suggested that excess TNF, a molecule which amplifies the inflammatory response, is centrally involved in sciatica and other forms of disc-related and neuropathic pain.

The Walter Reed study, published in the May 2009 issue of the journal Anesthesiology(2), provides the first randomized, double-blind, placebo-controlled data supporting the novel concept that etanercept could be used locally for a neurology indication. This concept was pioneered and patented not by the drug's manufacturer, but rather by Dr. Tobinick at the Institute for Neurological Research in Los Angeles. For the past ten years he has been, and is currently, using locally administered etanercept for treatment of patients with intractable sciatica, back and neck pain(3,4,5,6). This type of off-label use is an example of a repositioned use of an existing therapeutic, a topic of increasing interest to the pharmaceutical industry(7).

Also this week, in the May 5, 2009 issue of the journal Neuroscience, Kato and colleagues from the University of California, San Diego(8) reported that locally administered etanercept reaches the inside of injured nerves and reduces pain-related behavior in animals. The Neuroscience study cites three of the previous scientific publications of Dr. Tobinick(3,5,6). These new studies therefore provide further scientific support for the concept of local therapeutic administration of etanercept for disc-related pain.

These publications provide substantial new scientific data. However, FDA-approval is a long and difficult process, and prior to approval drug manufacturers are prohibited by the FDA from promoting any off-label use of any of their medications to the public. Nevertheless, the prospect of a new, non-surgical approach for chronic sciatica is exciting, and further investigation is already underway.

References

1. Cohen, S.P., N. Bogduk, A. Dragovich, C.C. Buckenmaier, 3rd, S. Griffith, C. Kurihara, J. Raymond, P.J. Richter, N. Williams, and T.L. Yaksh, Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26.
2. U.S. patent 6,419,944, filed April 5, 2001; also 6,537,549; and 6,982,089, issued to Edward Tobinick MD and assigned to TACT IP, LLC, and additional patents and related applications, assigned to TACT IP, LLC.   
3. Tobinick, E.L. and S. Britschgi-Davoodifar, Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly, 2003. 133(11-12): p. 170-7.
4. Tobinick, E.L., Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther, 2003. 25(4): p. 1211-8.
5. Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
6. Tobinick, E., Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today, 2009. 14(3-4): p. 168-77.
7. Tobinick, E., The value of drug repositioning in the current pharmaceutical market. Drug News and Perspectives 2009 Mar-Apr 22(2).
8. Kato, K., S. Kikuchi, V.I. Shubayev, and R.R. Myers, Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience, 2009. 160(2): p. 492-500.

Further information:

Institute for Neurological Research®, a private medical group, inc.
Los Angeles, California 90095
Telephone:    (310) 824-6199

Website: http://www.instituteforneurologicalresearch.com

Perispinal and epidural administration of etanercept for sciatica are off-label and are patented inventions (see reference 2 above) of Edward Tobinick, MD.

###

Read the full story at http://www.prweb.com/releases/sciatica/etanercept/prweb2377304.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Experimental Antidepressants Offer Faster Relief
2. Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy
3. AmeriCares Airlifts Relief to Nicaragua and Honduras
4. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
5. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
6. ThermoTx Introduces New Mobile Stimulation (TENS) Product Line for On the Go Therapy and Pain Relief
7. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
8. AmeriCares and International Medical Corps Airlift Relief for Cholera Outbreak In Iraq
9. MyoMed Launches Flash Virtual Tour of Toxin-Free Pain Relief
10. Friends of WFP Welcomes World Hunger Relief Week
11. Nicotine, Chili Peppers Offer Post-Surgery Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: